RADICAVA® Oral Suspension Receives Positive Recommendation from INESSS

Mitsubishi Tanabe Pharma Canada announces today they have received a positive recommendation from the Institut national d’excellence en santé et en services sociaux (INESSS) for RADICAVA® Oral Suspension for the treatment of patients with Amyotrophic lateral sclerosis (ALS). Full details on the recommendation by INESSS, including recommended criteria for reimbursement, are available on the INESSS website: https://www.inesss.qc.ca/en/index.html

RADICAVA® Oral Suspension is the first and only oral treatment option for ALS to receive a positive recommendation from INESSS. Mitsubishi Tanabe Pharma Canada continues working closely with the necessary stakeholders to make RADICAVA® Oral Suspension accessible to patients through private insurance and public formularies as quickly as possible, following commercial availability.

Read the full press release: https://www.mt-pharma-ca.com/wp-content/uploads/2022/12/MTP-CA_Press-Release_INESSS-Recommendation_RADICAVA-Oral-Suspension-2.pdf